SCHEMBL3685875

SCHEMBL3685875

O=Cc1c(O)cccc1I

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 12/20 0.45
TRIM24 O15164 1/20 0.43
TRIM33 Q9UPN9 1/20 0.43
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
PADI4 Q9UM07 1/20 0.39
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
TTR P02766 1/20 0.36
ADAMTS4 O75173 1/20 0.36
EGFR P00533 1/20 0.36
LMNA P02545 1/20 0.36
FYN P06241 1/20 0.36
MMP2 P08253 1/20 0.36
MMP9 P14780 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6902686 0.83 ALDH1A1 (0.48) ERN1ALDH1A1TDP1MEN1KMT2A
SCHEMBL311198 0.83 ERN1 (0.54) ERN1TRIM24TRIM33ALDH1A1TDP1
Charcoal, Activated SCHEMBL29407959 0.80 ERN1 (0.52) ERN1TRIM24TRIM33ALDH1A1TDP1
SCHEMBL30541650 0.80 ERN1 (0.52) ERN1TRIM24TRIM33ALDH1A1TDP1
SCHEMBL29220003 0.80 ERN1 (0.52) ERN1TRIM24TRIM33ALDH1A1TDP1
SCHEMBL30522433 0.80 ERN1 (0.52) ERN1TRIM24TRIM33ALDH1A1TDP1
Water SCHEMBL30515441 0.78 ERN1 (0.50) ERN1TRIM24TRIM33ALDH1A1TDP1
SCHEMBL1302180 0.74 ERN1 (0.64) ERN1TRIM24TRIM33ALDH1A1TDP1
SCHEMBL5153352 0.74 MEN1 (0.48) ERN1TRIM24TRIM33ALDH1A1TDP1
SCHEMBL412923 0.73 TRPA1 (0.50) ERN1TRIM24TRIM33ALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. 2025-09-18 US disclosed
WO-2025090658-A2 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF TERREMOTO BIOSCIENCES, INC. (US) 2025-05-01 WO disclosed
EP-2970308-B1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2021-07-14 EP disclosed
EP-2970196-B1 COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN GLOBAL BLOOD THERAPEUTICS INC (US) 2020-11-25 EP disclosed
WO-2010056788-A1 ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289789-A1 REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF CDK2, CDK20, CDK1 ERN1 1389/4885TRIM24 2997/4885TRIM33 1711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.